Combination Therapy with Romiplostim, Danazol, and a Thrombopoietin Receptor Agonist for Immune Restoration in Chronic Refractory Immune Thrombocytopenia: A Case Series
Romiplostim in combination with danazol and hetrombopag or eltrombopag may be a safe and efficacious therapy for chronic refractory primary immune thrombocytopenia; however, this needs to be further explored.
Authors
- Yechao Tu
- Genmei Tan
- Fei Li (ORCID: https://orcid.org/0000-0002-7765-5975)
- Shixuan Wang (ORCID: https://orcid.org/0000-0002-8610-952X)
- Xing Xie (ORCID: https://orcid.org/0000-0002-1636-4816)
- Lifang Zou (ORCID: https://orcid.org/0000-0002-0480-0094)
- Zhimin Zou (ORCID: https://orcid.org/0000-0002-6182-6346)
- Fancong Kong
Institutions
- Nanchang University (CN)
- Nanchang Center for Disease Control and Prevention (CN)
- First Affiliated Hospital of Nanchang University (CN)
Publication Details
- Journal
- ImmunoTargets and Therapy
- Published
- 2025-10-01
- DOI
- https://doi.org/10.2147/itt.s543982
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Health Commission of Jiangxi Province